ValueSet-2.16.840.1.113762.1.4.1234.50

Sourceus.nlm.vsac#0.11.0:null (v4.0.1)
resourceTypeValueSet
id2.16.840.1.113762.1.4.1234.50
canonicalhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.50
version20220106
statusactive
publisherBEST System Steward
nameCOVID19VaccineCodesForExposureIdentification
titleCOVID19 vaccine codes for exposure identification
date2022-01-06T01:02:20-05:00
experimentalfalse
Usages(none)

This value set contains 28 concepts

Code System Display
  0001A http://www.ama-assn.org/go/cpt Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose
  0002A http://www.ama-assn.org/go/cpt Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose
  0003A http://www.ama-assn.org/go/cpt Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose
  0011A http://www.ama-assn.org/go/cpt Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose
  0012A http://www.ama-assn.org/go/cpt Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose
  0013A http://www.ama-assn.org/go/cpt Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose
  0031A http://www.ama-assn.org/go/cpt Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; single dose
   207 http://hl7.org/fhir/sid/cvx SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose
   208 http://hl7.org/fhir/sid/cvx SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose
   210 http://hl7.org/fhir/sid/cvx SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL
   212 http://hl7.org/fhir/sid/cvx SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL
   213 http://hl7.org/fhir/sid/cvx SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED
   217 http://hl7.org/fhir/sid/cvx SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation
   218 http://hl7.org/fhir/sid/cvx SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation
   219 http://hl7.org/fhir/sid/cvx SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation
  2468235 http://www.nlm.nih.gov/research/umls/rxnorm SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension
  2470234 http://www.nlm.nih.gov/research/umls/rxnorm SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension
  2479835 http://www.nlm.nih.gov/research/umls/rxnorm SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML Injectable Suspension
  2583743 http://www.nlm.nih.gov/research/umls/rxnorm SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.05 MG/ML Injectable Suspension
  91300 http://www.ama-assn.org/go/cpt Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use
  91301 http://www.ama-assn.org/go/cpt Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use
  91303 http://www.ama-assn.org/go/cpt Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use
  XW013S6 http://www.cms.gov/Medicare/Coding/ICD10 Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  XW013T6 http://www.cms.gov/Medicare/Coding/ICD10 Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  XW013U6 http://www.cms.gov/Medicare/Coding/ICD10 Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  XW023S6 http://www.cms.gov/Medicare/Coding/ICD10 Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
  XW023T6 http://www.cms.gov/Medicare/Coding/ICD10 Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
  XW023U6 http://www.cms.gov/Medicare/Coding/ICD10 Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6

Produced 08 Sep 2023